Clinuvel Pharmaceuticals Limited announced the completion of development for ZEROKIN™, a proprietary single-use subcutaneous administration device designed for controlled-release formulations. The company has submitted an intellectual property application and plans to appoint a commercial manufacturer while preparing a Class II FDA 510(k) dossier and CE marking application. This initiative supports Clinuvel's pipeline of melanocortin peptides, including afamelanotide, by enabling versatile delivery options for hospital and self-administration use. Clinuvel is a global biopharmaceutical company focused on developing innovative therapies for genetic, metabolic, and dermatological disorders.

Clinuvel Pharmaceuticals provided an update on the clinical development of SCENESSE (afamelanotide) for vitiligo. The company is completing the CUV105 late-stage study, which enrolled 210 patients globally, with topline results anticipated in December 2026. This study evaluates SCENESSE combined with adjuvant narrowband UVB against the standard of care in patients with darker skin types. The pivotal Phase III CUV107 study is scheduled to begin in November 2026, following EMA protocol review, and will recruit 300 patients over 12 months. Clinuvel Pharmaceuticals is a global biopharmaceutical company focused on developing therapies for genetic, metabolic, and dermatological disorders, primarily utilizing melanocortin peptides.

Clinuvel Pharmaceuticals Limited announced a strategic reorganization effective January 1, 2027, which includes relocating its corporate headquarters to the United States and reducing its global workforce by 10% to 20%. The company aims to pivot its operational resources exclusively toward its U.S. pharmaceutical pipeline and commercial strategy to access deeper capital markets and higher valuation multiples. Clinuvel Pharmaceuticals is a global biopharmaceutical company focused on developing therapies for genetic, metabolic, and dermatological disorders.